Cooley is advising Horizon Pharma on its acquisition of Crealta Holdings for $510 million in cash. The transaction, which is subject to the satisfaction of customary closing conditions and regulatory approvals, is anticipated to close in the first quarter of 2016.
"The Crealta acquisition further diversifies our portfolio of medicines and aligns with our focus of acquiring value-enhancing, clinically differentiated, long-life medicines that treat orphan diseases," said Timothy P Walbert, chairman, president and chief executive officer of Horizon Pharma.
Horizon Pharma, headquartered in Dublin, Ireland, is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases.
Cooley has a longstanding relationship advising Horizon, including taking the company public in 2011. Earlier this year, Cooley advised Horizon on its acquisition of Hyperion Therapeutics for $1.1 billion, the company's largest acquisition to date. Cooley helped Horizon fund this acquisition through several equity and debt financings. In 2014, Cooley advised Horizon in its acquisition of Vidara Therapeutics for $660 million.